Every material Form 8-K Krystal Biotech filed with the SEC in 2023, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Krystal Biotech reported third quarter 2023 results, with net income of $80.7 million, or $2.88 per basic share, compared with a net loss of $29.9 million a year earlier. The result was driven by a $100 million gain from the sale of a Priority Review Voucher, while the company's loss from operations was $26.0 million and its first VYJUVEK product revenue was $8.6 million. Cash, cash equivalents and investments totaled $598.6 million at September 30, 2023.
Q3 2023 net income was $80.7 million, including a $100 million gain from the sale of a Priority Review Voucher.
Q3 2023 product revenues, net were $8.6 million, with 284 VYJUVEK Patient Start Forms received as of the end of the quarter.
Nine-month 2023 net income was $2.2 million, compared with a net loss of $107.9 million for the same period in 2022.
Krystal Biotech disclosed that Andrew Orth, its Chief Commercial Officer, resigned and that his last day with the company was August 2, 2023. The filing does not give a reason for the departure or name a successor, and it does not describe any financial impact.
Andrew Orth, Chief Commercial Officer, resigned from his position.
Orth's last day with Krystal Biotech was August 2, 2023.
The filing does not name a replacement or state a reason for the resignation.
Krystal Biotech reported a second-quarter 2023 net loss of $33.2 million, or $(1.25) per share, up from $28.1 million, or $(1.10) per share, a year earlier. The filing reports no revenue figure; it cites 121 Patient Start Forms for VYJUVEK in the first six weeks after its May 19 FDA approval, and $505.9 million in cash, cash equivalents and investments at June 30, 2023.
Q2 2023 net loss was $33.2 million, or $(1.25) per share, versus $28.1 million, or $(1.10) per share, in Q2 2022.
General and administrative expenses rose to $25.9 million from $17.9 million, and R&D expenses rose to $12.1 million from $10.9 million.
As of June 30, the company had received 121 VYJUVEK Patient Start Forms, 30 of them for dominant dystrophic epidermolysis bullosa.
Cash, cash equivalents and investments totaled $505.9 million on June 30, 2023.
On May 21, 2023, Krystal Biotech agreed to sell 1,729,729 shares of common stock to institutional investors at $92.50 per share, for an aggregate purchase price of approximately $160 million before offering expenses. The company plans to use the proceeds for commercialization of VYJUVEK, its clinical pipeline, business development, and working capital, and expects the sale to close on May 22, 2023. The new shares add to the company's outstanding share count, which dilutes existing shareholders, while the company says the funds should support operations through the end of 2026.
1,729,729 shares of common stock to be sold at $92.50 per share, for approximately $160 million in gross proceeds before offering-related expenses
Agreement dated May 21, 2023; closing expected May 22, 2023, subject to customary conditions
Financing led by Avoro Capital Advisors and Redmile Group, LLC, with participation from Braidwell LP and Frazier Life Sciences
Company agreed to file a registration statement for resale of the shares within 60 days of closing
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Krystal Biotech filing is on SEC EDGAR ↗. 8-K briefs of other companies →